

# Novo Nordisk – a focused healthcare company

Headline results from the REDEFINE 4 trial

# Forward-looking statements

Novo Nordisk's statutory Annual Report 2025, Form 20-F, any quarterly financial reports, and written information released, shown, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain certain forward-looking statements relating to the operating, financial and sustainability performance and results of Novo Nordisk and/or the industry in which it operates. Forward-looking statements can be identified by the fact that they do not relate to historical or current facts and include guidance. Words such as 'believe', 'expect', 'may', 'will', 'plan', 'strategy', 'transition plan', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'target' and other words and terms of similar meaning in connection with any discussion of future operating, financial or sustainability performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

- Statements of targets, future guidance, (transition) plans, objectives or goals for future operations, including those related to operating, financial and sustainability matters, Novo Nordisk's products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto;
- Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures;
- Statements regarding future economic performance, future actions and outcome of contingencies, such as legal proceedings; and
- Statements regarding the assumptions underlying or relating to such statements.


These statements are based on current plans, estimates, opinions, views and projections. Although Novo Nordisk believes that the expectation reflected in such forward-looking statements are reasonable, there can be no assurance that such expectation will prove to be correct. By their very nature, forward-looking statements involve risks, uncertainties and assumptions, both general and specific, and actual results may differ materially from those contemplated, expressed or implied by any forward-looking statement.

Factors that may affect future results include, but are not limited to, global as well as local political, economic and environmental conditions, such as interest rate and currency exchange rate fluctuations or climate change, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, including as a result of interruptions or delays affecting supply chains on which Novo Nordisk relies, shortages of supplies, including energy supplies, product recalls, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk's products, introduction of competing products, reliance on information technology including the risk of cybersecurity breaches, Novo Nordisk's ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, and taxation changes, including changes in tariffs and duties, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, strikes and other labour market disputes, failure to recruit and retain the right employees, failure to maintain a culture of compliance, epidemics, pandemics or other public health crises, effects of domestic or international crises, civil unrest, war or other conflict and factors related to the foregoing matters and other factors not specifically identified herein.

For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk's results or the accuracy of forward-looking statements in this Annual Report 2025, reference is made to the overview of risk factors in 'Risks' in the Annual Report 2025. None of Novo Nordisk or its subsidiaries or any such person's officers, or employees accept any responsibility for the future accuracy of the opinions expressed in the Annual Report 2025, Form 20-F, any quarterly financial reports, and written information released, shown, or oral statements made, to the public in the future by or on behalf of Novo Nordisk or the actual occurrence of the forecasted developments.

Unless required by law, Novo Nordisk has no duty and undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

# CagriSema demonstrated 23% weight loss in open label head-to-head REDEFINE 4 trial in people with obesity




### Trial objective and primary endpoint

- Confirm non-inferiority of CagriSema 2.4 mg/2.4 mg versus tirzepatide 15 mg
- Primary endpoint: change in body weight (%) from baseline to week 84


### Design considerations

- All investigators and participants were aware of the specific drug administered throughout the trial
- Protocol allowed for dose modification



# CagriSema adds to Novo Nordisk’s semaglutide-based AOM offerings and next generation pipeline

## A highly competitive semaglutide-based AOM offering



## Next generation AOM treatments in our development pipeline

Program	Biology	Phase
<b>Cagrilintide</b> (2.4 mg)	Amylin	Phase 3 initiated in Q4 2025
<b>Cagrilintide</b> HD	Amylin	Phase 3 initiation in H2 2026
<b>Zenagamtide</b> (sc./oral)	GLP-1/Amylin	Phase 3 initiation in H1 2026
<b>UBT251</b>	GLP-1/GIP/GCG	Phase 2 initiated in Q1 2026
<b>Triple</b>	GLP-1/GIP/Amylin	Phase 1b/2 ongoing

### Our key focus areas



Body weight loss



Safety and tolerability



Composition of weight loss



Dosing frequency

# Investor contact information

## Share information

Novo Nordisk's B shares are listed on the stock exchange in Copenhagen under the symbol 'NOVO B'. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'.

For further company information, visit Novo Nordisk on:  
[www.novonordisk.com](http://www.novonordisk.com)

## Upcoming events

26 March 2026	Annual General meeting
6 May 2026	Financial results for the first three months of 2026
5 August 2026	Financial results for the first six months of 2026
21 September 2026	Capital Markets Day 2026
4 November 2026	Financial results for the first nine months of 2026

## Investor Relations contacts

Novo Nordisk A/S  
Investor Relations  
Novo Alle 1  
DK-2880 Bagsværd

Michael Novod	+45 3075 6050	<a href="mailto:nvno@novonordisk.com">nvno@novonordisk.com</a>
Jacob Martin Wiborg Rode	+45 3075 5956	<a href="mailto:jrde@novonordisk.com">jrde@novonordisk.com</a>
Sina Meyer	+45 3079 6656	<a href="mailto:azey@novonordisk.com">azey@novonordisk.com</a>
Max Ung	+45 3077 6414	<a href="mailto:mxun@novonordisk.com">mxun@novonordisk.com</a>
Alex Bruce	+45 3444 2613	<a href="mailto:axeu@novonordisk.com">axeu@novonordisk.com</a>
Christoffer Sho Togo Tullin	+45 3079 1471	<a href="mailto:cftu@novonordisk.com">cftu@novonordisk.com</a>
Frederik Taylor Pitter (USA)	+1 609 613 0568	<a href="mailto:fptr@novonordisk.com">fptr@novonordisk.com</a>